By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche said today that it has partnered with Cellular Dyanmics and Acea Biosciences on technologies for the early and accurate prediction of cardiotoxic side effects in the drug discovery process.

The alliance will combine Cellular Dynamics' induced pluripotent stem cell-derived heart cells, called iCell Cardiomyocytes, with Roche's xCelligence RTCA System, a label-free cell analysis system which was co-developed by Acea.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.